Drug intelligence / Profile preview

GS-5885 + GS-9451

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

GS-5885 + GS-9451 is an oral investigational combination of two small molecule antivirals developed for the treatment of chronic hepatitis C virus (HCV) infection, specifically genotype 1. GS-5885 (ledipasvir) is an HCV NS5A inhibitor that blocks viral RNA replication and assembly, while GS-9451 is a selective HCV NS3 protease inhibitor that impedes viral protein processing. The combination was evaluated in several phase 2 clinical trials, both alone and with other antivirals such as tegobuvir and ribavirin, to determine its safety, tolerability, and antiviral efficacy in treatment-naive and treatment-experienced patients[2][4].

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on GS-5885 + GS-9451.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-5885 + GS-9451.

Explore the full profile